接受TIPS植入的患者中肺内血管扩张的高患病率及临床相关性
本研究纳入265例接受TIPS植入的患者,用对比增强超声心动图和血气分析判定肺内血管扩张(IPVD)和肝肺综合征(HPS),多变量竞争风险分析随访1年内心脏失代偿、肝脏失代偿及无肝移植生存。IPVD与心脏失代偿(HR 1.756)和肝脏失代偿(HR 1.841)风险升高相关,但无肝移植生存无差异;HPS组的失代偿趋势未达统计学显著。
要点
- 265例TIPS患者中136例存在IPVD,71例符合HPS标准。
- IPVD与心脏失代偿风险升高相关(HR 1.756;95%CI 1.011-3.048;P=.046)。
- IPVD与肝脏失代偿风险升高相关(HR 1.841;95%CI 1.255-2.701;P=.002)。
核心结论
- TIPS植入前筛查IPVD可能有助于进一步识别心脏失代偿和肝脏失代偿风险较高的患者。
研究设计与样本
- 研究纳入265例接受TIPS植入的患者,采用对比增强超声心动图和血气分析判定IPVD与HPS,并进行多变量竞争风险分析。
主要发现
- 265例患者中136例有IPVD,71例符合HPS标准;IPVD患者FIPS评分较低、肌酐较低,且更常因静脉曲张出血接受TIPS。
- IPVD与心脏失代偿风险升高相关(HR 1.756;95%CI 1.011-3.048;P=.046),与肝脏失代偿风险升高相关(HR 1.841;95%CI 1.255-2.701;P=.002)。
- 有无IPVD患者的无肝移植生存相当(HR 1.081;95%CI 0.630-1.855;P=.780)。
- HPS患者心脏失代偿(HR 1.708;95%CI 0.935-3.122;P=.082)和肝脏失代偿(HR 1.458;95%CI 0.934-2.275;P=.097)呈增多趋势但未达统计学显著。
- 有无HPS患者的无肝移植生存无差异(HR 1.052;95%CI 0.577-1.921;P=.870)。
关键数值与推荐
- IPVD与心脏失代偿的HR为1.756(95%CI 1.011-3.048;P=.046)。
- IPVD与肝脏失代偿的HR为1.841(95%CI 1.255-2.701;P=.002)。
- IPVD与无肝移植生存的HR为1.081(95%CI 0.630-1.855;P=.780)。
- HPS与心脏失代偿的HR为1.708(95%CI 0.935-3.122;P=.082)。
- HPS与肝脏失代偿的HR为1.458(95%CI 0.934-2.275;P=.097)。
临床怎么用
- 原文结论指出,TIPS植入前筛查IPVD可能有助于进一步识别心脏失代偿和肝脏失代偿风险较高的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Considerate patient selection is vital to ensure the best possible outcomes after transjugular intrahepatic portosystemic shunt (TIPS) insertion. However, data regarding the impact of intrapulmonary vascular dilatations (IPVDs) or hepatopulmonary syndrome (HPS) on the clinical course after TIPS implantation is lacking. Hence, this study aimed to investigate the relevance of IPVD and HPS in patients undergoing TIPS implantation. METHODS: Contrast enhanced echocardiography and blood gas analysis were utilized to determine presence of IPVD and HPS. Multivariable competing risk analyses were performed to evaluate cardiac decompensation (CD), hepatic decompensation (HD), and liver transplant (LTx)-free survival within 1 year of follow-up. RESULTS: Overall, 265 patients were included, of whom 136 had IPVD and 71 fulfilled the HPS criteria. Patients with IPVD had lower Freiburg index of post-TIPS survival (FIPS) scores, lower creatinine, and more often received TIPS because of variceal bleeding. Presence of IPVD was associated with a significantly higher incidence of CD (hazard ratio [HR], 1.756; 95% confidence interval [CI], 1.011-3.048; P = .046) and HD (HR, 1.841; 95% CI, 1.255-2.701; P = .002). However, LTx-free survival was comparable between patients with and without IPVD (HR, 1.081; 95% CI, 0.630-1.855; P = .780). Patients with HPS displayed a trend towards more CD (HR, 1.708; 95% CI, 0.935-3.122; P = .082) and HD (HR, 1.458; 95% CI, 0.934-2.275; P = .097) that failed to reach statistical significance. LTx-free survival did not differ in those with HPS compared with patients without HPS, respectively (HR, 1.052; 95% CI, 0.577-1.921; P = .870). CONCLUSION: Screening for IPVD before TIPS implantation could help to further identify patients at higher risk of CD and HD.
引用
- Mauz JB, Rieland H, Berliner D, et al. High Prevalence and Clinical Relevance of Intrapulmonary Vascular Dilatations in Patients Undergoing TIPS Implantation. Clin Gastroenterol Hepatol. 2024. PMID: 38729401. doi:10.1016/j.cgh.2024.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。